Vitalhub (VHI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
19 Mar, 2026Executive summary
Achieved total revenue of $108.97 million (CAD 100+ million) for 2025, a 59% increase year-over-year, with strong Q4 performance and successful integration of Novari and Induction acquisitions.
Annual recurring revenue (ARR) reached $96.1 million, up 35% year-over-year, with 10% net organic growth.
Adjusted EBITDA for the year was $26.55 million (24% margin), up 49% year-over-year.
Net income for 2025 was $6.11 million, more than doubling from the prior year.
AI initiatives and customer-driven projects are underway, expected to contribute to revenue from mid-2026 onward.
Financial highlights
Q4 2025 revenue was $31.39 million, up 52% year-over-year, with recurring revenue comprising 75% of total.
Q4 adjusted EBITDA was $7.43 million (24% margin), up 47% year-over-year.
Q4 gross margin was 79%, slightly down from 81% year-over-year.
Q4 net income was $4.07 million, up from $0.79 million in Q4 2024.
Cash and short-term investments at year-end totaled $119.18 million, with no debt.
Outlook and guidance
Targeting a return to pre-acquisition EBITDA margins of 27-28% and ARR growth of 10-12% as integration progresses.
Management expects further improvement in adjusted EBITDA margin in 2026 as acquisition integration continues.
Expecting incremental ARR and margin expansion through cost synergies and new AI-driven revenue streams.
Anticipates strong cash collections in Q2, driven by large renewals.
M&A activity remains a focus, with ongoing deal flow and disciplined valuation approach.
Latest events from Vitalhub
- Q2 revenue up 24% with 41% higher adjusted EBITDA and MedCurrent acquisition pending.VHI
Q2 20241 Feb 2026 - Growth through acquisitions and AI integration aims to boost recurring revenue and margins by 2026.VHI
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - Delivers $93.7M ARR and 22% EBITDA margin through global healthcare software and M&A.VHI
Investor presentation15 Jan 2026 - Q3 revenue and ARR up 25%, pro forma ARR at CAD 68M after acquisitions, strong cash position.VHI
Q3 202413 Jan 2026 - Healthcare IT firm achieves $70M+ ARR via acquisitions, organic growth, and high-margin solutions.VHI
Planet MicroCap Showcase: VEGAS 202527 Dec 2025 - ARR up 59% and revenue up 31% in 2024, with robust M&A and strong cash position.VHI
Q4 202426 Dec 2025 - Q1 2025 delivered robust ARR and revenue growth, with strong M&A momentum and cash position.VHI
Q1 202526 Nov 2025 - ARR up 55%, revenue up 47%, 26% EBITDA margin, and strong acquisition integration.VHI
Q2 202523 Nov 2025 - ARR up 75% YoY to CAD 93.7M; Q3 revenue up 94%; integration and margin focus ongoing.VHI
Q3 202513 Nov 2025